PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TSHA vs. OLMA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between TSHA and OLMA is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

TSHA vs. OLMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Taysha Gene Therapies, Inc. (TSHA) and Olema Pharmaceuticals, Inc. (OLMA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-27.60%
-59.31%
TSHA
OLMA

Key characteristics

Sharpe Ratio

TSHA:

0.11

OLMA:

-0.86

Sortino Ratio

TSHA:

1.05

OLMA:

-1.45

Omega Ratio

TSHA:

1.13

OLMA:

0.83

Calmar Ratio

TSHA:

0.12

OLMA:

-0.74

Martin Ratio

TSHA:

0.27

OLMA:

-1.86

Ulcer Index

TSHA:

42.64%

OLMA:

36.50%

Daily Std Dev

TSHA:

110.57%

OLMA:

78.69%

Max Drawdown

TSHA:

-98.14%

OLMA:

-96.26%

Current Drawdown

TSHA:

-94.87%

OLMA:

-90.88%

Fundamentals

Market Cap

TSHA:

$340.21M

OLMA:

$387.55M

EPS

TSHA:

$0.63

OLMA:

-$2.28

Total Revenue (TTM)

TSHA:

$6.31M

OLMA:

$0.00

Gross Profit (TTM)

TSHA:

$5.69M

OLMA:

-$182.00K

EBITDA (TTM)

TSHA:

-$69.51M

OLMA:

-$105.21M

Returns By Period

In the year-to-date period, TSHA achieves a -5.78% return, which is significantly higher than OLMA's -14.75% return.


TSHA

YTD

-5.78%

1M

0.00%

6M

-27.56%

1Y

2.52%

5Y*

N/A

10Y*

N/A

OLMA

YTD

-14.75%

1M

-9.96%

6M

-59.30%

1Y

-66.44%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

TSHA vs. OLMA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TSHA
The Risk-Adjusted Performance Rank of TSHA is 5252
Overall Rank
The Sharpe Ratio Rank of TSHA is 4949
Sharpe Ratio Rank
The Sortino Ratio Rank of TSHA is 5959
Sortino Ratio Rank
The Omega Ratio Rank of TSHA is 5656
Omega Ratio Rank
The Calmar Ratio Rank of TSHA is 5050
Calmar Ratio Rank
The Martin Ratio Rank of TSHA is 4848
Martin Ratio Rank

OLMA
The Risk-Adjusted Performance Rank of OLMA is 55
Overall Rank
The Sharpe Ratio Rank of OLMA is 66
Sharpe Ratio Rank
The Sortino Ratio Rank of OLMA is 55
Sortino Ratio Rank
The Omega Ratio Rank of OLMA is 77
Omega Ratio Rank
The Calmar Ratio Rank of OLMA is 66
Calmar Ratio Rank
The Martin Ratio Rank of OLMA is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TSHA vs. OLMA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Taysha Gene Therapies, Inc. (TSHA) and Olema Pharmaceuticals, Inc. (OLMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for TSHA, currently valued at 0.11, compared to the broader market-2.000.002.004.000.11-0.86
The chart of Sortino ratio for TSHA, currently valued at 1.05, compared to the broader market-6.00-4.00-2.000.002.004.006.001.05-1.45
The chart of Omega ratio for TSHA, currently valued at 1.13, compared to the broader market0.501.001.502.001.130.83
The chart of Calmar ratio for TSHA, currently valued at 0.12, compared to the broader market0.002.004.006.000.12-0.74
The chart of Martin ratio for TSHA, currently valued at 0.27, compared to the broader market-10.000.0010.0020.0030.000.27-1.86
TSHA
OLMA

The current TSHA Sharpe Ratio is 0.11, which is higher than the OLMA Sharpe Ratio of -0.86. The chart below compares the historical Sharpe Ratios of TSHA and OLMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50SeptemberOctoberNovemberDecember2025February
0.11
-0.86
TSHA
OLMA

Dividends

TSHA vs. OLMA - Dividend Comparison

Neither TSHA nor OLMA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

TSHA vs. OLMA - Drawdown Comparison

The maximum TSHA drawdown since its inception was -98.14%, roughly equal to the maximum OLMA drawdown of -96.26%. Use the drawdown chart below to compare losses from any high point for TSHA and OLMA. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%-75.00%SeptemberOctoberNovemberDecember2025February
-94.87%
-90.88%
TSHA
OLMA

Volatility

TSHA vs. OLMA - Volatility Comparison

The current volatility for Taysha Gene Therapies, Inc. (TSHA) is 20.83%, while Olema Pharmaceuticals, Inc. (OLMA) has a volatility of 22.20%. This indicates that TSHA experiences smaller price fluctuations and is considered to be less risky than OLMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
20.83%
22.20%
TSHA
OLMA

Financials

TSHA vs. OLMA - Financials Comparison

This section allows you to compare key financial metrics between Taysha Gene Therapies, Inc. and Olema Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab